UNSPSC 51282704: Dalbavancin

This classification denotes an antibacterial with the molecular formula C88H100Cl2N10O28, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 808UI9MS5K, chemically known as RISTOMYCIN A AGLYCONE,5,31-DICHLORO-38-DE(METHOXYCARBONYL)-7-DEMETHYL-19-DEOXY-56-O-(2-DEOXY-2-((10-METHYL-1-OXOUNDECYL)AMINO)-.BETA.-D-GLUCOPYRANURONOSYL)-38-(((3-(DIMETHYLAMINO)PROPYL)AMINO)CARBONYL)-42-O-.ALPHA.-D-MANNOPYRANOSYL-N(SUP 15)-METHYL- but generally known as dalbavancin, which bears US NIH Compound Identifier 23724878.

UNSPSC 51282704 Dalbavancin, a Commodity code, shows minimal recent state and local procurement activity directly aligned with the code's pharmaceutical scope. The recent opportunities tagged to this code include naloxone and drug deactivation systems procurement, pharmacy benefit management and direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceutical contracting — none of which center on dalbavancin, an antibiotic used to treat bacterial skin infections. State and local governments procuring under this code are purchasing pharmaceutical products and medical supplies through a mix of issuing bodies: county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), municipal fire departments (City of Tampa), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The work involves establishing term contracts for pharmaceutical supply, competitive bidding for medical consumables, and information-gathering for direct manufacturer relationships.

Geographic activity spans Florida, Texas, Minnesota, and Oregon across the recent opportunities. Representative solicitations include Seminole County's IFB 60459723LAS (due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries to the county health building; Texas HHS Commission's RFI HHS0017013 (response deadline April 3, 2026) exploring direct-to-manufacturer prescription capabilities for state employee pharmacy benefits; City of Tampa's IFB 26-P-00145 (due March 13, 2026) for medical and first aid supplies estimated at $700,000 with a 5 percent bid discount set-aside for certified Small Local Business Enterprises; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across state and local government facilities. The code shows limited recent activity specifically targeting dalbavancin as a named product line.